SANGAMO THERAPEUTICS, INC
Customers
4
0 disclosed
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Latest period
Sep 30, 2020
10-Q filed 2020-11-04
Customers 4
Companies SGMOQ discloses as major customers, as a share of SGMOQ revenue. 0 active, 4 lapsed.
| Company | % of SGMOQ revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| PFE PFIZER INC |
68% | $39.3M | 3M 2020-09-30 | +50.0pp | Lapsed Last seen 2020-09-30 |
10-Q 2020-11-04 |
Pfizer 68 % 16 % 51 % 11 % Pfizer 18 % 26 % 21 % 16 % Pfizer 27 % N/A During 2018, revenues related to our hemophilia A collaboration agreement with Pfizer and the collaboration agreement with Kite represented 45% and 30%, respectively, of our total revenues. For the three months ended September 30, 2018, revenues related to the Company's hemophilia A collaboration agreement with Pfizer, Kite and Sanofi represented 44%, 38% and 10%, respectively, of the Company’s total revenue. For the three months ended June 30, 2018, revenues related to the Company’s hemophilia A collaboration agreement with Pfizer, Kite and the hemoglobinopathies agreement with Sanofi represented 38%, 35% and 21%, respectively, of the Company’s total revenue. During the three months ended March 31, 2018, revenues related to the Company’s hemophilia A collaboration agreement with Pfizer and the hemoglobinopathies agreement with Sanofi represented 61% and 35%, respectively, of the Company’s total revenue. During 2017, revenues related to Pfizer and Bioverativ represented 47% and 34%, respectively, of our total revenues. | ||||||
| GILD GILEAD SCIENCES, INC. |
13% | $7.5M | 3M 2020-09-30 | −21.0pp | Lapsed Last seen 2020-09-30 |
10-Q 2020-11-04 |
Kite Pharma, Inc. 13 % 40 % 24 % 55 % Kite Pharma, Inc. 34 % 52 % 42 % 61 % Kite Pharma, Inc. 55 % 75 % During 2018, revenues related to the hemophilia A collaboration agreement with Pfizer Inc. (“Pfizer”) and Kite Pharma, Inc. (“Kite”), a wholly-owned subsidiary of Gilead Sciences, Inc., represented 45% and 30%, respectively, of the Company’s total revenue. | ||||||
| Dow Agrosciences Llc Non-SEC Dow Agrosciences Llc |
12% | $2.9M | FY 2013-12-31 | −10.0pp | Lapsed Last seen 2013-12-31 |
10-K 2015-02-25 |
During 2013, revenues related to Shire, Sigma-Aldrich Corporation (Sigma) and Dow AgroSciences LLC (DAS) represented 68%, 9% and 12%, respectively, of total revenues. | ||||||
| SNY Sanofi |
3% | $1.7M | 3M 2020-09-30 | −5.0pp | Lapsed Last seen 2020-09-30 |
10-Q 2020-11-04 |
Sanofi 3 % 40 % 4 % 29 % Sanofi 8 % 17 % 7 % 18 % Sanofi 4 % 18 % For the three months ended September 30, 2018, revenues related to the Company's hemophilia A collaboration agreement with Pfizer, Kite and Sanofi represented 44%, 38% and 10%, respectively, of the Company’s total revenue. For the three months ended June 30, 2018, revenues related to the Company’s hemophilia A collaboration agreement with Pfizer, Kite and the hemoglobinopathies agreement with Sanofi represented 38%, 35% and 21%, respectively, of the Company’s total revenue. During the three months ended March 31, 2018, revenues related to the Company’s hemophilia A collaboration agreement with Pfizer and the hemoglobinopathies agreement with Sanofi represented 61% and 35%, respectively, of the Company’s total revenue. | ||||||
Alerts are coming
Get an email when SGMOQ's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.